Treatment of erectile dysfunction in men with diabetes mellitus Review article

Article Sidebar

Requires Subscription PDF (Język Polski)


Published: Mar 31, 2013

Main Article Content

Krzysztof Dęmbe
Katedra i Klinika Gastroenterologii i Chorób Przemiany Materii, Warszawski Uniwersytet Medyczny
Przemysław Krasnodębski
Katedra i Klinika Gastroenterologii i Chorób Przemiany Materii, Warszawski Uniwersytet Medyczny
Mariusz Jasik
Katedra i Klinika Gastroenterologii i Chorób Przemiany Materii, Warszawski Uniwersytet Medyczny
Waldemar Karnafel
Katedra i Klinika Gastroenterologii i Chorób Przemiany Materii, Warszawski Uniwersytet Medyczny

Abstract

Erectile dysfunction (ED) is defined as the inability to achieve and maintain an erection sufficient for sexual intercourse. ED is an important cause of decreased quality of life. Erectile dysfunction is common complication of diabetes, in prevalence ranging between 20–75%. ED affects diabetic men 10–15 y earlier than the general population. The etiology of ED in diabetes mellitus is multifactorial, with neurovascular, endocrinological factors playing a prominent role. Pathophysiological mechanisms underlying diabetes-associated ED are in large part due to endothelial dysfunction. The therapy of ED should be directed toward the specific cause. For the treatment of ED can been used phosphodiesterase type 5 (PDE5) inhibitor, vacuum erectile devices, intracorporeal injection therapy, vascular surgery, penile prostheses. In hypogonadal men with diabetes mellitus therapy with testosterone is often effective.

Downloads

Download data is not yet available.

Article Details

How to Cite
Dęmbe , K., Krasnodębski , P., Jasik , M., & Karnafel , W. (2013). Treatment of erectile dysfunction in men with diabetes mellitus. Cardiology in Practice, 7(1), 43-48. Retrieved from https://journalsmededu.pl/index.php/kwp/article/view/1577
Issue
Vol 7 No 1 (2013)
Section
Articles
Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Copyright: © Medical Education sp. z o.o. This is an Open Access article distributed under the terms of the Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). License (https://creativecommons.org/licenses/by-nc/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.

Address reprint requests to: Medical Education, Marcin Kuźma (marcin.kuzma@mededu.pl)

References

1. Feldman H.A., Goldstein I.: Hatzichristan D.G., McKinlay J.B.: Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging Study. J. Urol. 1994, 151: 54-61.
2. Lew-Starowicz Z., Skrzypulec V.: Podstawy seksuologii. PZWL, Warszawa 2010.\
3. Dęmbe K., Jasik M., Stawicki S., Karnafel W.: Patogeneza i częstość zaburzeń erekcji u chorych na cukrzycę. Seksuologia Polska 2004, 2: 2.
4. Carson C., Kirby R., Goldstein J.: Textbook of erectile dysfunction. Isis Medical Media, Oxford 1999.
5. De Tejada I., Goldstein J., Azadoi K. et al.: Impaired neurogenic and endothelium mediated relaxation of penile smooth muscle from diabetic men with impotence. N. Engl. J. Med. 1989, 320: 1025-1030.
6. Hoffman F.: The molecular basis of second messenger system for regulation of smooth muscle contractility; state of the heart lecture. J. Hypertension 1985, 3: 53-58.
7. Musicki B., Burnett Al.: Endothelial dysfunction in diabetic erectile dysfunction. Intrnational Journal of Impotence Research 2007, 19: 129-138.
8. Dęmbe K., Jasik M., Karnafel W.: Metody diagnostyki i terapii zaburzeń erekcji u pacjentów z cukrzycą. Przewodnik Lekarza 2005; 3(75): 66-74.
9. Kapor D., Aldred H., Clark S. et al.: Clinical and biochemical assessment of hypogonadism in men with type 2 diabetes. Diabetes Care 2007, 30(4): 911-917.
10. Corona G., Mannuci E., Petrone L. et al.: Associacion of hypogonadism and type II diabetes in men attending an outpatient erectile dysfunction clinic. International Journal of Impotence Research 2006, 18: 190-197.
11. Dęmbe K., Jasik M., Niebisz A., Karnafel W.: Wpływ niektórych leków na występowanie zaburzeń erekcji u pacjentów z cukrzycą. Seksuologia Polska 2010, 8(1): 20-25.
12. Lew-Starowicz Z.: Zaburzenia seksualne w praktyce ogólnolekarskiej. Termedia, Poznań 2004.
13. Jacson G., Rosen R.C., Kloner R.A.: The second Princeton consensus on sexual dysfunction and cardiac risk: new guidelines for sexual medicine. J. Sex. Med. 2006, 3: 28-36.
14. Fonseca V., Sefted A., Denne J.: Impact of diabetes mellitus on the severity of erectile dysfunction and response to treatment; analysis of data from tadalafil clinical trials. Diabetologia 2004, 47: 1914-1923.
15. Goldstein I., Jay J., Fischer K. et al.: Verdenafil, a new phosphodiesterase type 5 inhibitor, in the treatment of erectile dysfunction in men with diabetes. Diabetes Care 2003, 26: 777-783.
16. Behrend L., Vibe-Petrsen J., Perrild H.: Sildenafil in the treatment of erectile dysfunction in men with diabetes: demand, efficacy and patient satisfaction. International journal of Impotence Research 2005, 17: 264-269.
17. Saenz I., Anglin G., Knight J. et al.: Effects of tadalafil on erectile dysfunction in men with diabetes. Diabetes Care 2002, 25: 2159-2164.
18. Dęmbe K., Pacuła P., Karnafel W., Czyżyk A.: Ocena długoterminowego stosowania iniekcji prostaglandyny E1 w leczeniu impotencji erekcyjnej u chorych na cukrzycę. Diabetologia Polska, 1995, 2: 283-287.
19. Bivalacqua T., Musicki B., Usta M. et al.: Endothelial nitric oxide synthase gene therapy for erectile dysfunction. Current Pharmaceutical Design 2005, 11: 4059-4067.